Complicaciones en pacientes usuarios de traqueostomía en unidades de cuidados intensivos. Scoping Review / Complications associated with tracheostomy in adult patients in intensive care units between 2015-2020. A Scoping Review / Complicações associadas à traqueostomia em pacientes adultos em unidades de terapia intensiva no período 2015-2020. Revisão sistemática

Introducción: Los procedimientos de traqueostomía van en aumento en las unidades de cuidados intensivos en el adulto, por lo que las complicaciones asociadas a este procedimiento también incrementan. Se ha identificado que la traqueostomía puede conllevar a complicaciones tanto preoperatorias como postoperatorias, que varían ampliamente entre un 5-40%, entre las más frecuentes están, estenosis traqueal, fístula traqueoesofágica, hemorragia, lesión peristomal, decanulación, infecciones, entre otras, que podrían causar la muerte hasta en 1,4% de las personas. Sin embargo, a nivel mundial muy pocos estudios abordan los conceptos causales o factores de riesgo mecánicos y no mecánicos de este importante tema. Objetivo: Revisar el alcance de la literatura científica disponible sobre las complicaciones de origen mecánico y no mecánico asociadas a la traqueostomía en pacientes adultos en las unidades de cuidados intensivos entre el periodo 2015-2020. Materiales y métodos: se establecieron la pregunta de investigación con metodología "Patient, Intervention, Comparation, Outcome, Time (PICOT)" y los criterios de inclusión para la búsqueda de los referentes bibliográficos de estudios observacionales y experimentales. La información fue consultada en las bases de datos PubMed y EBSCO y los artículos científicos seleccionados fueron los publicados entre los años 2015-2020. Como guía metodológica y de calidad para el presente estudio se utilizó la lista de chequeo PRISMA-ScR. Resultados: las complicaciones con mayor frecuencia son: sangrado 61% presentada (13/21 artículos), estenosis traqueal 28,5% (5/21 artículos), decanulación 23,6% (5/21 artículos), infección de la estoma 19% (4/21 artículos) muerte 19% (4/21) y la dificultad en la inserción de la cánula 19% (4/21 artículos), en cuanto a factores de riesgo mecánicos para éstas sólo se identifica el uso de la técnica Bjork flap (OR=0,4). Entre los no mecánicos se encontraron, obesidad (OR=5,15), diámetro de cánula >6 (OR= 2,6) y ventilación mecánica preoperatoria (OR=3,14). Conclusión:Se logró identificar que las complicaciones relacionadas con la traqueostomía con mayor incidencia son sangrado, estenosis traqueal, decanulación accidental y la muerte. Sin embargo, aún se desconoce si se originan por una causa mecánica o no mecánica durante su manejo en UCI.

Introduction:Tracheostomy procedures in intensive care units are on the rise; however, they can lead to both perioperative and postoperative complications, with a variable incidence from 5 to 40% and even death in up to 1.4% of individuals. Despite this, few studies address causal concepts or mechanical and nonmechanical risk factors about this important topic. Objetive: To review the scope of the available scientific literature on complications of mechanical and non-mechanical origin associated with a tracheostomy. Materials and Methods:The research question and inclusion criteria were established to conduct the search in PubMed and EBSCO databases between 2015 and 2020. The PRISMA-ScR checklist was used in the present study as a methodological and quality guideline. Results:The most frequent complications were bleeding 61%, tracheal stenosis 28.5%, decannulation 23.6% (5/21) , stoma infection 19%, death 19%, and difficult tracheostomy tube insertion 19%. Regarding mechanical risk factors, only the use of the Bjork flap (OR=0.4) was identified as a protective factor. Among the non-mechanical factors, obesity (OR=5.15), tube diameter >6 (OR=2.6), and preoperative mechanical ventilation (OR=3.14) were found. Conclusions: It was possible to identify that the highest incidence of tracheostomy-related complications were bleeding, tracheal stenosis, accidental decannulation, and death; however, it is still unknown whether they originate from a mechanical or non-mechanical cause during intensive care management.

Introdução: Os procedimentos de traqueostomia estão aumentando nas unidades de terapia intensiva, entretanto, podem levar a complicações perioperatórias e pós-operatórias com uma incidência variável entre 5-40% e até a morte em até 1,4% dos indivíduos, apesar disso, poucos estudos abordam os conceitos causais ou fatores de risco mecânicos e não-mecânicos sobre este importante tópico. Objetivo: Rever o escopo da literatura científica disponível sobre complicações mecânicas e não mecânicas associadas à traqueostomia. Materiais e Métodos: a questão da pesquisa e critérios de inclusão foram estabelecidos para a pesquisa nas bases de dados PubMed e EBSCO entre os anos 2015-2020, como guia metodológico e de qualidade para o presente estudo foi utilizada a lista de verificação PRISMAScR. Resultados: As complicações com maior freqüência foram, sangramento 61%, estenose traqueal 28,5%, decanulação 23,6% (5/21, infecção por estoma 19%, morte 19% e dificuldade na inserção da cânula 19%, em relação aos fatores de risco mecânico, apenas o uso da técnica de Bjork Flap (OR=0,4) foi identificado como fator de proteção, entre os fatores não mecânicos foram encontrados: obesidade (OR=5,15), diâmetro da cânula >6 (OR= 2,6) e ventilação mecânica pré-operatória (OR=3,14). Conclusões: Conseguimos identificar que as complicações relacionadas à traqueostomia com maior incidência foram sangramento, estenose traqueal, decanulação acidental e morte, no entanto, ainda não se sabe se elas se originam de uma causa mecânica ou não mecânica durante a gestão dos cuidados intensivos.

Clinical Proof of Concept for Stabilization of Tracheostomy Tubes Using Novel DYNAtraq Device.

Introduction: Tracheostomy is one of the most common surgical strategies in intensive care units (ICU) and provides relevant clinical benefit for multiple indications. However, the complications associated with its use range from 5 to 40% according to different series. The risk of these complications could be reduced if fixation strategies and alignment of the tracheostomy tube with respect to the tracheal axis are improved. Aim: To build a functional device of technological innovation in respiratory medicine for the fixation and alignment of tracheostomy cannula (acronym DYNAtraq) and to evaluate its feasibility and safety in a pilot study in mechanically ventilated patients. Methods: Study carried out in four phases: (1) design engineering and functional prototyping of the device; (2) study of cytotoxicity and tolerance to the force of traction and push; (3) pilot study of feasibility and safety of its use in tracheostomized and mechanically ventilated patients; and (4) health workers satisfaction study. Results: The design of the innovative DYNAtraq device included, on the one hand, a connector with very little additional dead space to be inserted between the cannula and the ventilation tubes, and, on the other hand, a shaft with two supports for adhesion to the skin of the thorax with very high tolerance (several kilograms) to pull and push. In patients, the device corrected the malpositioned tracheostomy tubes for the latero-lateral (p < 0.001) and cephalo-caudal angles (p < 0.001). Its effect was maintained throughout the follow-up time (p < 0.001). The use of DYNAtraq did not induce serious adverse events and showed a 70% protective effect for complications (RR = 0.3, p < 0.001) in patients. Conclusion: DYNAtraq is a new device for respiratory medicine that allows the stabilization, alignment and fixation of tracheostomy tubes in mechanically ventilated patients. Its use provides additional benefits to traditional forms of support as it corrects misalignment and increases tolerance to habitual or forced movements. DYNAtraq is a safe element and can reduce the complications of tracheostomy tubes.

Differences in health policies for drug availability in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension across Latin America.

Treatment for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension in Latin America differs between countries, with regard to disease etiology, health insurance coverage, and drug availability. A group of experts from Latin America, met to share regional experiences and propose possible lines of collaboration. The available evidence, regional clinical practice data, and the global context of the proceedings of the 6th World Symposium on Pulmonary Hypertension, held in Nice, France, in February 2018, were analyzed. Here, we discuss some priority concepts identified that could guide transnational interaction and research strategies in Latin America: (1) despite being evidence-based, the 6th World Symposium on Pulmonary Hypertension proceedings may not be applicable in Latin American countries; (2) proactive identification and diagnosis of patients in Latin America is needed; (3) education of physicians and standardization of appropriate treatment for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension is vital; (4) our clinical experience for the treatment strategy for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension is based on drug availability in Argentina, Brazil, Colombia and México; (5) there are difficulties inherent to the consultation of patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension, and access to treatment; (6) the importance of data generation and research of Latin American-specific issues related to pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension is highlighted.

Effect of Antioxidants in the Treatment of COPD Patients: Scoping Review.

Chronic obstructive pulmonary disease (COPD) is a common, preventable, treatable lung disease characterized by persistent respiratory symptoms and airflow limitation and multiorgan impact. This affects the nutritional status of patients and requires multidimensional interventions including nutritional interventions according to individual metabolic needs. Our scoping review determined the effects of antioxidants in the treatment of COPD patients and their role in the decrease in the probability of exacerbations, hospital readmissions, and changes in lung function. The sources MEDLINE, LILACS, and Google Scholar were consulted and 19 studies were selected. The most indicated antioxidants are N-Acetylcysteine, vitamins E and D, and Zinc. Other antioxidants from plants or fruits extracts are also being investigated. The beneficial effect of antioxidants in stable or exacerbated patients is not clear, but theoretical and biological arguments of benefit justify lines of research that specify the impact on reducing oxidative stress and negative effects in COPD.

Invention and Pilot Study of the Efficacy and Safety of the SUPRAtube Device in Continuous Supraglottic Aspiration for Intubated and Mechanically Ventilated Patients.

BACKGROUND: Bronchoaspiration of content that accumulates in the supraglottic area (eg, saliva, gastroesophageal reflux) is a risk factor for ventilator-associated pneumonia. A continuous supraglottic suction system may decrease the risk of bronchoaspiration in these patients. OBJECTIVE: (1) Constructing a conceptual model and functional prototype of a continuous supraglottic suction device for use in humans; (2) defining functional characteristics in ex vivo swine head models; and (3) evaluating its efficacy and safety in mechanically ventilated patients. METHODS: Study conducted in three phases. First phase: definition of distances and diameters of the triangle determined by dental arch, posterior oropharynx and vallecula, and diameter of the oropharynx in axial projection; and identification of the declining area of supraglottic suction. Second phase: design engineering and functional prototype evaluated in ex vivo models. Third phase: evaluation of device use in terms of safety and efficacy in ventilated patients. RESULTS: We obtained a final functional model of the SUPRAtube device injected into PVC for medical use. Device effectiveness in in vitro simulation showed a high and fast suction capacity of liquid and thick volumes. Study of swine heads allowed to validate the shape, size and functional fenestration of the device. Study in intubated and mechanically ventilated patients showed a high supraglottic suction capacity and the absence of local adverse events during 72 (7-240) hours of continuous operation. CONCLUSION: Our study describes the process of conceptualization, design and production of a practical, safe, low-cost continuous supraglottic suction device without representing antibiotic pressure, which appears to be a new complementary preventive strategy for the standard management of intubated and mechanically ventilated patients.

[Chronic exposure to altitude. Clinical characteristics and diagnosis]. / Exposición crónica a la altura. Características clínicas y diagnóstico

Chronic exposure to altitude has been associated with hypobaric hypoxia in its inhabitants. Two entities have been associated with it, high altitude pulmonary hypertension and chronic mountain sickness. Its physiological and pulmonary circulation characteristics are described, as well as its clinical profile and diagnosis.

La exposición crónica a la altitud se ha asociado a hipoxia hipobárica en quienes la experimentan. Dos entidades se han asociado a la hipoxia hipobárica: la hipertensión pulmonar de la alta altitud y el mal de montaña crónico. Se describen sus características fisiológicas y de la circulación pulmonar, así como su perfil clínico y el diagnóstico.

Consenso Colombiano para la prevención, diagnóstico y manejo de condiciones trombóticas en pacientes adultos con COVID-19: aplicando el Marco de la Evidencia a la Decisión (EtD) GRADE / Colombian consensus for the prevention, diagnosis and treatment of thrombotic conditions in adult patients with COVID-19: applying GRADE Evidence to Decision (EtD) Frameworks

resumen está disponible en el texto completo

Abstract Recent studies have reported the occurrence of thrombotic phenomena or coagulopathy in patients with COVID-19. There are divergent positions regarding the prevention, diagnosis, and treatment of these phenomena, and current clinical practice is based solely on deductions by extension from retrospective studies, case series, observational studies, and international guidelines developed prior to the pandemic. In this context, the aim was to generate a group of recommendations on the prevention, diagnosis and management of thrombotic complications associated with COVID-19. Methods: A rapid guidance was carried out applying the GRADE Evidence to Decision (EtD) frameworks and an iterative participation system, with statistical and qualitative analysis. Results: 31 clinical recommendations were generated focused on: a) Coagulation tests in symptomatic adults with suspected infection or confirmed SARS CoV-2 infection; b) Thromboprophylaxis in adults diagnosed with COVID-19 (Risk scales, thromboprophylaxis for outpatient, in-hospital management, and duration of thromboprophylaxis after discharge from hospitalization), c) Diagnosis and treatment of thrombotic complications, and d) Management of people with previous indication of anticoagulant agents. Conclusions: Recommendations of this consensus guide clinical decision-making regarding the prevention, diagnosis, and treatment of thrombotic phenomena in patients with COVID-19, and represent an agreement that will help decrease the dispersion in clinical practices according to the challenge imposed by the pandemic.

Experience with veno-venous ecmo in patients with adult respiratory distress syndrome secondary to viral pneumonia. Case series / Experiencia con ecmo veno-venoso en pacientes con síndrome de dificultad respiratoria del adulto secundario a neumonía viral. Serie de casos

Abstract Introduction The use of extracorporeal membrane oxygenation (ECMO) has increased exponentially in recent years and has shown to be effective in treating adult respiratory distress syndrome (ARDS) secondary to HiNi-related pneumonia. However, evidence remains controversial. This study describes a case series of ECMO in ARDS secondary to viral pneumonia. Methods A search was conducted in the ECMO database of Fundación Cardiovascular de Colombia for the 20132017 period. A case series report was written of patients diagnosed with ARDS secondary to confirmed or suspected viral pneumonia. Results Nineteen patients with ECMO support and ARDS due to viral pneumonia were included in the study. The survival rate upon discharge was 11 patients (58%) and weaning from ECMO support was successful in 13 patients (68%). Hemorrhagic complications were the most frequent: gastrointestinal bleeding, 10 patients (53%); intracranial bleeding, 2 (10%); alveolar hemorrhage, 2 (10%);' hemothorax requiring thoracostomy with chest tube drainage, 2 (10%); cannulation site bleeding, 9 patients (47%); and surgical site bleeding in 3 patients (25%) who required tracheostomy. Other complications were: pneumothorax, 1 patient (5%); sepsis, 6 patients (32%); and growth of microorganisms in bronchial lavage, 6 patients (32%). Conclusions This study supports the use of veno-venous ECMO to achieve a higher survival rate than expected in patients with severe ARDS and refractory hypoxemia secondary to viral pneumonia. Early initiation of the therapy should improve overall results.

Resumen Introducción El uso de la oxigenación por membrana extracorpórea (ECMO) ha tenido un incremento exponencial en los últimos años y ha demostrado ser efectivo en el manejo del síndrome de dificultad respiratoria del adulto (SDRA) secundario a neumonía por H1N1, si bien la evidencia sigue siendo controvertida. En este estudio describimos una serie de casos de ECMO por SDRA secundario a neumonía viral. Métodos Se realizó una búsqueda en la base de datos de ECMO de la Fundación Cardiovascular desde el año 20132017. Reportamos una serie de casos donde se incluyeron pacientes diagnosticados con SDRA secundario a neumonía viral sospechosa o confirmada. Resultados Se incluyeron en el estudio 19 pacientes con soporte de ECMO y SDRA por neumonía viral. La sobrevida al alta fue 11 pacientes (58%) y el destete del ECMO fue exitoso en 13 pacientes (68%). Las complicaciones hemorrágicas presentadas fueron: sangrado digestivo, 10 pacientes (53%), sangrado cerebral, 2 (10%), hemorragia alveolar, 2 (10%), hemotórax con requerimiento de toracostomía a drenaje cerrado, 2 (10%), sangrado activo por sitio de canulación, 9 pacientes (53%), y 3 pacientes traqueostomizados (25%) que sangraron por el sitio quirúrgico. Otras complicaciones presentadas fueron: neumotórax, 1 paciente (5%), septicemia, 6 (32%) y crecimiento de microorganismos en lavados bronquiales 6 (32%). Conclusion El presente estudio permite indicar que el uso de la ECMO VV viabiliza una sobrevida mayor a la esperada en pacientes con SDRA severo e hipoxemia refractaria secundario a neumonía viral. Su inicio tempranamente debe mejorar los resultados globales.

Terapia con fibrinólisis local dirigida por catéter en tromboembolismo pulmonar de riesgo intermedio / Therapy with local fibrinolysis directed by catheter in intermediate risk pulmonary thromboembolism

Resumen Introducción: en pacientes con tromboembolia pulmonar (TEP) aguda, la fibrinólisis arterial local puede tener una relación muy favorable entre beneficios y riesgos. Objetivo: caracterizar las condiciones epidemiológicas y clínicas de los pacientes con TEP agudo de riesgo intermedio que han recibido terapia fibrinolítica urgente dirigida por catéter. Métodos: estudio descriptivo de una serie de casos de pacientes atendidos en la Fundación Cardiovascular de Colombia (período 2012-2016) con diagnóstico de TEP de riesgo intermedio llevados a terapia fibrinolítica mediante catéter pulmonar. Resultados: se incluyeron 27 casos (26 pacientes, 57±20 años, 52% mujeres). La confirmación de embolia pulmonar aguda se realizó mediante angiotomografía. El 85% de los casos mostró signos ecocardiográficos de disfunción ventricular derecha, 74% elevación de troponinas, y 82% elevación de BNP o pro-BNP. El tiempo puerta-aguja desde el diagnóstico hasta la fibrinólisis fue de 29±31 horas (máx-min, 2-120). El tratamiento endovascular incluyó alteplasa (dosis total, 47±18 mg) y fragmentación-aspiración mecánica mediante catéter pulmonar. El 78% de los pacientes mostró disminuciones en la PAPm >10% del valor inicial [i.e., pacientes respondedores, ΔPAPm=-27±11% (-9±5 mmHg)]. Cinco pacientes fueron clasificados como no-respondedores (ΔPAPm=-2±7%, -1±4 mmHg). La estancia en UCI fue de 7±5 días (1-19), y la hospitalaria 13 días (1-36). No se presentaron complicaciones de sangrado mayor ni de otra índole. La supervivencia a 90 días fue de 100%. Conclusiones: esta serie observa que la fibrinólisis arterial pulmonar induce una mejoría hemodinámica inmediata en una alta proporción de pacientes con TEPa, con un balance beneficio-riesgo favorable en ausencia de complicaciones atribuibles inmediatas o tardías. (Acta Med Colomb 2019; 44: 17-24).

Abstract Introduction: in patients with acute pulmonary embolism (PE), local arterial fibrinolysis can have a very favorable relationship between benefits and risks. Objective: to characterize the epidemiological and clinical conditions of patients with intermediate-risk of acute PE who have received urgent fibrinolytic therapy directed by catheter. Methods: a descriptive study of a series of cases of patients treated at the Cardiovascular Foundation of Colombia (2012-2016 period) with a diagnosis of intermediate-risk PE who received fibrinolytic therapy using a pulmonary catheter. Results: 27 cases were included (26 patients, 57 ± 20 years, 52% women). Confirmation of acute pulmonary embolism was performed by angiotomography. 85% of the cases showed echocardiographic signs of right ventricular dysfunction, 74% elevation of troponins, and 82% elevation of BNP or pro-BNP. The door-needle time from diagnosis to fibrinolysis was 29 ± 31 hours (max-min, 2-120). The endovascular treatment included alteplase (total dose, 47 ± 18 mg) and mechanical fragmentation-aspiration by pulmonary catheter. 78% of the patients showed decreases in PAPm> 10% of the initial value [i.e., responding patients, ΔPAPm = -27 ± 11% (-9 ± 5 mmHg)]. Five patients were classified as non-responders (ΔPAPm = -2 ± 7%, -1 ± 4 mmHg). The stay in the ICU was 7 ± 5 days (1-19), and the hospital stay was 13 days (1-36). There were no complications of major or other bleeding. The 90-day survival was 100%. Conclusions: this series shows that pulmonary arterial fibrinolysis induces an immediate hemodynamic improvement in a high proportion of patients with intermediate-risk PE with a favorable benefit-risk balance in the absence of immediate or delayed attributable complications. (Acta Med Colomb 2019; 44: 17-24).

Combined aerobic exercise and high-intensity respiratory muscle training in patients surgically treated for non-small cell lung cancer: a pilot randomized clinical trial.

BACKGROUND: Lung resection surgery further decreases exercise capacity and negatively affects respiratory muscle function in patients with non-small cell lung cancer (NSCLC). The best design for exercise interventions in these patients has not been determined yet. AIM: To assess the impact of aerobic exercise and high-intensity respiratory muscle training on patient outcomes following lung cancer resection surgery. DESIGN: Prospective, single-blind, pilot randomized controlled trial. SETTING: Outpatient cardiopulmonary rehabilitation unit of two university hospitals. POPULATION: Thirty-seven patients with NSCLC after tumor resection. METHODS: Patients were randomly assigned to exercise training or usual post-operative care. The training program consisted of aerobic exercises and high-intensity respiratory muscle training (24 supervised sessions, 3 per week, 8 weeks). Primary outcome was exercise capacity assessed with peak oxygen uptake (VO2peak) during cardiopulmonary exercise test. Secondary outcomes included changes in respiratory muscle strength, levels of serum insulin growth factor I (IGF-I) and IGF binding protein 3 (IGFBP-3), and quality of life assessed with the European Organization for Research and Treatment of Cancer (EORTC QLQ-C30) questionnaire. RESULTS: The 8-week training program was associated with significant improvement in VO2peak (2.13 mL/Kg/min [95%CI 0.06 to 4.20]), maximal inspiratory and expiratory pressures (18.96 cmH2O [95% CI 2.7 to 24.1] and 18.58 cmH2O [95% CI 4.0 to 33.1], respectively) and IGFBP-3 (0.61 µg/mL [%95 CI 0.1 to 1.12]). No significant differences were observed in the EORTC QLQ-C30. CONCLUSIONS: An 8-week exercise program consisting of aerobic exercise and high-intensity respiratory muscle training improved exercise capacity, respiratory muscle strength, and serum IGFBP-3 levels in NSCLC patients after lung resection. There was no impact on the other outcomes assessed. CLINICAL REHABILITATION IMPACT: A combination of aerobic exercise and respiratory muscle training could be included in the rehabilitation program of deconditioned patients with NSCLC after lung resection surgery.

Bispectral index in hypercapnic encephalopathy associated with COPD exacerbation: a pilot study.

BACKGROUND: Hypercapnic encephalopathy is relatively frequent in severe exacerbations of COPD (ECOPDs), with its intensity usually being evaluated through clinical scales. Bispectral index (BIS) is a relatively new technique, based on the analysis of the electroencephalographic signal, which provides a good approximation to the level of consciousness, having already been validated in anesthesia. OBJECTIVE: The objective of the study was to evaluate the utility of BIS in the assessment of the intensity of hypercapnic encephalopathy in ECOPD patients. PATIENTS AND METHODS: A total of ten ECOPD patients were included, and the level of brain activity was assessed using BIS and different scales: Glasgow Coma Scale, Ramsay Sedation Scale (RSS), and Richmond Agitation-Sedation Scale. The evaluation was performed both in the acute phase and 3 months after discharge. RESULTS: BIS was recorded for a total of about 600 minutes. During ECOPD, BIS values ranged from 58.8 (95% CI: 48.6-69) for RSS score of 4 to 92.2 (95% CI: 90.1-94.3) for RSS score of 2. A significant correlation was observed between values obtained with BIS and those from the three scales, although the best fit was for RSS, followed by Glasgow and Richmond (r=-0.757, r=0.701, and r=0.615, respectively; P<0.001 for all). In the stable phase after discharge, BIS showed values considered as normal for a wake state (94.6; 95% CI: 91.7-97.9). CONCLUSION: BIS may be useful for the objective early detection and automatic monitoring of the intensity of hypercapnic encephalopathy in ECOPD, facilitating the early detection and follow-up of this condition, which may avoid management problems in these patients.

El síndrome de apneas-hipoapneas del sueño (SAHS) grave incrementa la excreción urinaria de eritropoyetina. Efecto del tratamiento con CPAP / Increased Urinary Erythropoietin Excretion in Severe Sleep Apnea-Hipoapnea Syndrome: The Effect of CPAP

Introducción: La hipoxia tisular estimula la producción de eritropoyetina (EPO) que tiene como principal función estimular la eritropoyesis. El SAHS es una entidad caracterizada por la presencia de episodios repetidos de hipoxemia durante el sueño. Objetivo: Analizar si dicha hipoxemia es un estímulo suficiente para incrementar la excreción urinaria de EPO. Si la respuesta fuera positiva, valorar si el tratamiento con presión continua positiva de la vía aérea (CPAP) la inhibiría. Métodos: Se han estudiado 25 sujetos con sospecha de SAHS, a los que se les realizó un estudio polisomnográfico. En todos ellos se determinaron los niveles de EPO en la primera orina de la mañana (uEPO), así como los niveles de creatinina y hemoglobina en sangre. En los pacientes con SAHS grave se repitieron las mismas determinaciones tras el tratamiento con CPAP. Resultados: Doce sujetos fueron diagnosticados de SAHS grave (media ± SD, IAH de 53,1 ± 22,7). La creatinina y la hemoglobina fueron normales en todos los sujetos. La uEPO fue cuatro veces superior en el grupo SAHS respecto a los controles (1,32 ± 0,83 vs. 0,32 ± 0,35 IU/l, p < 0,002). El tratamiento con CPAP descendió la uEPO hasta 0,61 ± 0,49 IU/l (p < 0,02), acercándose al valor de los sujetos sanos. No se observó una relación dosis-respuesta entre la gravedad de las alteraciones de la PSG y los valores de uEPO. Conclusiones: Los pacientes con SAHS grave muestran un incremento en su excreción de uEPO, que se normaliza tras el tratamiento con CPAP

Introduction: Tissue hypoxia stimulates the production of erythropoietin (EPO), the main effect of which is, in turn, to stimulate erythropoiesis. Sleep apnea-hypopnea syndrome (SAHS) is an entity characterized by repeated episodes of hypoxemia during sleep. Objective: To analyze whether hypoxemia stimulated increased urinary excretion of EPO, and if so, to evaluate if treatment with continuous positive airway pressure (CPAP) can inhibit this phenomenon. Methods: We studied 25 subjects with suspected SAHS who underwent a polysomnography study (PSG). EPO levels in first morning urine (uEPO) and blood creatinine and hemoglobin were determined in all patients. Patients with severe SAHS repeated the same determinations after CPAP treatment. Results: Twelve subjects were diagnosed with severe SAHS (mean ± SD, AHI 53.1 ± 22.7). Creatinine and hemoglobin levels were normal in all subjects. uEPO was 4 times higher in the SAHS group than in the control group (1.32 ± 0.83 vs. 0.32 ± 0.35 UI/l, p <.002). CPAP treatment reduced uEPO to 0.61 ± 0.9 UI/l (p <.02), levels close to those observed in healthy subjects. No dose-response relationship was observed between severity of PSG changes and uEPO values. Conclusions: Patients with severe SAHS show increased uEPO excretion, but this normalizes after treatment with CPAP

Correction to: Real-World Switching to Riociguat: Management and Practicalities in Patients with PAH and CTEPH.

The original version of this article unfortunately contained a mistake. In the "Results" section, the percentage of patients with inoperable or persistent/recurrent CTEPH included in the study was reported as 85%. This has been corrected to 68% with this erratum.

Real-World Switching to Riociguat: Management and Practicalities in Patients with PAH and CTEPH.

PURPOSE: A proportion of patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) do not achieve treatment goals or experience side effects on their current therapy. In such cases, switching patients to a new drug while discontinuing the first may be a viable and appropriate treatment option. CAPTURE was designed to investigate how physicians manage the switching of patients to riociguat in real-world clinical practice. Observations from the study were used to assess whether recommendations in the riociguat prescribing information are reflected in clinical practice. METHODS: CAPTURE was an international, multicenter, uncontrolled, retrospective chart review that collected data from patients with PAH or inoperable or persistent/recurrent CTEPH who switched to riociguat from another pulmonary hypertension (PH)-targeted medical therapy. The primary objective of the study was to understand the procedure undertaken in real-world clinical practice for patients switching to riociguat. RESULTS: Of 127 patients screened, 125 were enrolled in CAPTURE. The majority of patients switched from a phosphodiesterase type 5 inhibitor (PDE5i) to riociguat and the most common reason for switching was lack of efficacy. Physicians were already using the recommended treatment-free period when switching patients to riociguat from sildenafil, but a slightly longer period than recommended for tadalafil. In line with the contraindication, the majority of patients did not receive riociguat and PDE5i therapy concomitantly. Physicians also followed the recommended dose-adjustment procedure for riociguat. CONCLUSION: Switching to riociguat from another PH-targeted therapy may be feasible in real-world clinical practice in the context of the current recommendations.

Increased Urinary Erythropoietin Excretion in Severe Sleep Apnea-Hipoapnea Syndrome: The Effect of CPAP. / El síndrome de apneas-hipoapneas del sueño (SAHS) grave incrementa la excreción urinaria de eritropoyetina. Efecto del tratamiento con CPAP.

INTRODUCTION: Tissue hypoxia stimulates the production of erythropoietin (EPO), the main effect of which is, in turn, to stimulate erythropoiesis. Sleep apnea-hypopnea syndrome (SAHS) is an entity characterized by repeated episodes of hypoxemia during sleep. OBJECTIVE: To analyze whether hypoxemia stimulated increased urinary excretion of EPO, and if so, to evaluate if treatment with continuous positive airway pressure (CPAP) can inhibit this phenomenon. METHODS: We studied 25 subjects with suspected SAHS who underwent a polysomnography study (PSG). EPO levels in first morning urine (uEPO) and blood creatinine and hemoglobin were determined in all patients. Patients with severe SAHS repeated the same determinations after CPAP treatment. RESULTS: Twelve subjects were diagnosed with severe SAHS (mean ± SD, AHI 53.1 ± 22.7). Creatinine and hemoglobin levels were normal in all subjects. uEPO was 4 times higher in the SAHS group than in the control group (1.32 ± 0.83 vs. 0.32 ± 0.35 UI/l, p <.002). CPAP treatment reduced uEPO to 0.61 ± 0.9 UI/l (p <.02), levels close to those observed in healthy subjects. No dose-response relationship was observed between severity of PSG changes and uEPO values. CONCLUSIONS: Patients with severe SAHS show increased uEPO excretion, but this normalizes after treatment with CPAP.

Calidad de vida en adultos mayores con enfermedad pulmonar obstructiva crónica / Quality of life in older adults with chronic obstructive pulmonary disease / Qualidade de vida em idosos com doença pulmonar obstrutiva crônica

Introducción: Laenfermedad pulmonar obstructiva crónica es una importante causa de mortalidad y morbilidad a nivel mundial y tiene efectos psicosociales y fisiopatológicos que repercuten de manera significativa en la calidad de vida de quienes la padecen. Objetivo:Evaluar la calidad de vida de pacientes con enfermedad pulmonar obstructiva crónica a través del instrumento SF-36, versión en español para Colombia (SF-36 v2), en un servicio de consulta externa de Floridablanca, Colombia, durante el año 2015. Metodología: Estudio de corte transversal descriptivo realizado en 40 pacientes con diagnóstico de enfermedad pulmonar obstructiva crónica que asistieron al servicio de consulta externa por Neumología entre los meses de febrero y noviembre de 2015. El cuestionario SF-36 v2 fue diligenciado por todos los participantes; previamente, se firmó el consentimiento informado. La base de datos fue digitada, bajo licencia, en QualityMetric Health Outcomes™ Scoring Software 4.0. Resultados: Participaron 40 pacientes, con una edad media de 73 (DE ± 8.4) años. En las dimensiones de funcionamiento físico se encontraron valores inferiores a 50; por otra parte, las dimensiones Funcionamiento Social y Rol Emocional presentaron valores superiores y cercanos a los reportados por población sana. Conclusiones:Los pacientes con enfermedad pulmonar obstructiva crónica mostraron una disminución en la calidad de vida comparado con los valores de referencia en población en general en sus dos componentes: físico y mental. Se ratifica el impacto que tiene esta enfermedad en todas las subescalas que componen este constructo, especialmente en el componente físico

Introduction: Chronic obstructive pulmonary disease is one the most significant causes of mortality and morbidity worldwide. It has psychosocial and pathophysiological effects that impact in a significant way to those who suffer from it. Objective: To evaluate quality of life from patients suffering from chronic obstructive pulmonary disease through the SF-36 survey (Spanish version for Colombia (SF-36 v2)) made during an external medical appointment made in Floridablanca, Colombia in 2015. Methodology:Descriptive cross sectional study performed to 40 patients diagnosed with chronic obstructive pulmonary disease. These patients attended to external pulmonology medical appointments between February and November of 2015 and filled out the short form SF-36 v2 after signing informed consent. The database was created under license using QualityMetric Health Outcomes™ Scoring Software 4.0. Results: 40 patients, with an average age of 73 years (DE ± 8.4), participated in this study. When analyzing data, it was found that the physical functioning dimensions were values lower than 50. On the other hand, it was found that dimensions related to social functioning and emotional role had higher values and close to the ones reported by healthy population. Conclusions: Patients diagnosed with chronic obstructive pulmonary disease showed a decrease in quality of life, in both of its dimensions: physical and mental, compared to healthy population's reference values. It is ratified that this disease impacts all sub-scales of this construct, specially the ones related to the physical component

Introdução: Adoença pulmonar obstrutiva crônica é uma importante causa de mortalidade e morbidade em todo o mundo e tem efeitos psicossociais e fisiopatológicos que têm um impacto significativo na qualidade de vida daqueles que sofrem com ela. Objetivo: Avaliar a qualidade de vida de pacientes com doença pulmonar obstrutiva crônica através do instrumento SF-36, versão em espanhol para a Colômbia (SF-36 v2), em um serviço ambulatorial de Floridablanca, Colômbia, durante 2015. Metodologia:Estudo descritivo de corte transversal feito em 40 pacientes com diagnóstico de doença pulmonar obstrutiva crônica que compareceram ao ambulatório de Pneumologia entre os meses de fevereiro e novembro de 2015. O questionário SF-36 v2 foi preenchido por todos os participantes; anteriormente, o consentimento informado foi assinado. O banco de dados foi digitado, sob licença, em Quality Metric Health Outcomes™ Scoring Software 4.0. Resultados:Participaram 40 pacientes, com média de idade de 73 (DE ± 8.4) anos. Nas dimensões do funcionamento físico, valores menores que 50 foram encontrados; por outro lado, as dimensões do Funcionamento Social e do Papel Emocional apresentaram valores superiores e próximos aos relatados pela população saudável. Conclusões: Os pacientes com doença pulmonar obstrutiva crônica apresentaram diminuição da qualidade de vida em relação aos valores de referência na população geral em seus dois componentes: físico e mental. O impacto desta doença em todas as subescalas que compõem este construto, especialmente no componente físico, é confirmado

Extracorporeal Membrane Oxygenation in Dengue, Malaria, and Acute Chagas Disease.

Extracorporeal membrane oxygenation (ECMO) is widely used in acute respiratory distress syndrome (ARDS) and myocarditis. Severe vector-mediated diseases may be complicated by ARDS or myocarditis, which are both associated with a high mortality rate. We present six cases of severe dengue, malaria, and acute Chagas disease that were treated with ECMO from September 2007 to September 2015. Patients included two pediatric and four adults (aged 12-48). Survival to decannulation was 83% and to discharge was 66%. Overall, the mean duration on ECMO was 25.4 days. We conclude that ECMO treatment can be beneficial in patients with severe dengue, malaria, and acute Chagas disease, if complicated by pulmonary or cardiac complications.

Disfunción muscular respiratoria en pacientes llevados a cirugía cardiovascular / Respiratory muscle dysfunction in patients undergoing cardiovascular surgery

Resumen Objetivo: Evaluar la presencia de las alteraciones en la fuerza muscular respiratoria en pacientes programados para la cirugía cardiovascular, el impacto de la cirugía sobre la función muscular respiratoria y su relación con las alteraciones ventilatorias en el postoperatorio mediato. Métodos: Estudio observacional prospectivo. Se realizaron pruebas de funcionalismo respiratorio (espirometría) y pruebas de fuerza muscular respiratoria (inspiratoria: presión inspiratoria máxima y espiratoria: presión espiratoria máxima) en dos momentos: preoperatorio inmediato (2 ± 1 días precirugía) y postoperatorio mediato (2 ± 1 días, antes del alta). Las complicaciones respiratorias incluyeron: la ventilación mecánica prolongada, el tromboembolismo pulmonar, el neumotórax, el hemotórax, la neumonía, el derrame pleural, el edema pulmonar y las atelectasias. Resultados: Se evaluaron 30 pacientes adultos (n = 30) (62 ± 12 años). En el preoperatorio la capacidad espirométrica disminuyó en un 54% (35% alteración obstructiva, 19% no- obstructiva) y la debilidad inspiratoria y espiratoria fue confirmada en un 67 y 100%, respectivamente. Las complicaciones respiratorias estuvieron presentes en un 93% (con mayor frecuencia la atelectasia y el derrame pleural). El deterioro postoperatorio grave de la presión inspiratoria máxima incrementó 10 veces el riesgo de atelectasia (OR = 10, IC 95% 0,85-117,02; p = 0,067). Al alta, la fracción de eyección del ventrículo izquierdo fue 29% menor, la capacidad vital forzada -32%, la presión inspiratoria máxima -32% y la presión espiratoria máxima -32% con respecto al valor inicial. Conclusiones: Los pacientes llevados a la cirugía cardiovascular tienen una insospechada disfunción de los músculos respiratorios que empeora con la cirugía y la hospitalización, que se asocia a un incremento del riesgo de complicaciones respiratorias.

Abstract Motivation: To assess the presence of alterations in respiratory muscle strength in patients with a programmed cardiovascular surgery, the impact of the surgery on respiratory muscle function and their relationship with ventilatory alterations during mediate postoperative period. Methods: Prospective observational study. Respiratory function tests (spirometry) and respiratory muscle strength tests (inspiratory: maximum inspiratory pressure, and expiratory: maximum expiratory pressure) were conducted in two moments: immediate preoperative (2 ± 1 days before surgery) and mediate postoperative period (2 ± 1, before being discharged). Respiratory complications included prolonged mechanical ventilation, pulmonary thromboembolism, pneumothorax, hemothorax; pneumonia; pleural effusion; pulmonary edema and atelectases. Results: 30 adult patients were assessed (n = 30) (ages 62 ± 12). Spirometry performance decreased by 54% in the preoperative period (35% obstructive alteration, 19% non-obstructive) and inspiratory and expiratory weakness was confirmed at 67 and 100% respectively. Respiratory complications were present in 93% (more frequently atelectasis and pleural effusion). Severe postoperative deterioration of maximum inspiratory pressure increased by 10-fold the risk of atelectasis (OR = 10, IC 95% 0.85-117.02; p = 0.067). Upon discharge, ejection fraction of the left ventricle was 29% lower, forced vital capacity -32%, maximum inspiratory pressure -32% and maximum expiratory pressure -32% with regards to baseline values. Conclusion: Patients undergoing cardiovascular surgery suffer an unsuspected respiratory muscle dysfunction that worsens with surgery and hospitalisation, associated to a increase of the risk of respiratory complications.

TriBURTER: invención y validación perceptual del dispositivo portátil de vibración de alta frecuencia y entrenamiento muscular para pacientes con enfermedades respiratorias / TriBURTER: invention and perceptual validation of a portable device aimed to induce high- frequency vibration and respiratory muscle training in patients with respiratory diseases

Introducción: los dispositivos respiratorios vibrátiles son útiles como elementos de terapia respiratoria pues facilitan la expectoración de las secreciones bronquiales. Un dispositivo respiratorio de vibración que incorpore válvulas duales representa una innovación relevante respecto a los modelos existentes. El presente estudio describe la invención y evaluación de un nuevo dispositivo médico portátil de vibración de alta frecuencia para uso humano que permite simultáneamente el entrenamiento muscular respiratorio para pacientes con enfermedades respiratorias, al que se ha denominado con el acrónimo TriBURTER. Métodos: se conceptualizaron, diseñaron y construyeron modelos virtuales y prototipos funcionales siguiendo metodología de bioingeniería y evaluación in situ del funcionamiento a través de simuladores electrónicos. Adicionalmente se evaluaron, mediante escalas psicométricas específicas, los aspectos perceptuales de la morfología y funcionamiento del dispositivo tanto en voluntarios sanos como pacientes. Resultados: se creó un dispositivo que logra tres efectos: facilitar la movilización de secreciones bronquiales, inducir efecto de entrenamiento sobre los músculos inspiratorios, e inducir entrenamiento de músculos espiratorios. La evaluación perceptual demostró que el diseño final del dispositivo es seguro, adecuado, suficiente y práctico. Conclusión: TriBURTER es un dispositivo médico innovador de terapia respiratoria vibrátil que facilita el drenaje de secreciones y genera una sobrecarga muscular, tanto inspiratoria como espiratoria, regulable y útil en el tratamiento de las enfermedades respiratorias, y que puede ser aplicado tanto en ámbito ambulatorio como domiciliario u hospitalario. Su evaluación perceptual demostró seguridad clínica y una adecuada aceptación de uso por parte de los voluntarios sanos y pacientes en términos de cualidad y funcionamiento. MÉD.UIS. 2016;29(2):49-57.

Introduction: vibratory devices are used in respiratory therapy in order to facilitate removal of bronchial secretions. A portable hydraulic system incorporating inspiratory and expiratory valves could provide additional advantages over existing ones. The present study describes the invention and evaluation of a new portable medical device able to induce high frequency vibration and allowing respiratory muscle training for patients with respiratory diseases, which has been named with the acronym TriBURTER. Methods: based on conventional methods of bioengineering, a hydraulic device was conceptualized, designed, built, and validated using electronic simulators. In addition, perceptual evaluations of morphology, final prototype design and function were evaluated in both healthy volunteers and patients through specific psychometric scales. Results: a hydraulic device including two unidirectional valves was finally obtained allowing to induce simultaneously a triple effect: mobilization of bronchial secretions, inspiratory muscle training, and expiratory muscle training. Perceptual evaluations showed that the final design is safe, adequate, sufficient and practical. Conclusion: TriBURTER is an innovative hydraulic medical device for respiratory therapy that facilitates drainage of secretions and generates adjustable inspiratory and expiratory muscle loads. The perceptual evaluations of the device showed proper acceptance of use by healthy volunteers and patients in terms of quality and performance. This device is useful for the treatment of respiratory diseases and can be prescribed for both outpatient and domiciliary or hospital settings. MÉD.UIS. 2016;29(2):49-57.